{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:00:35Z","timestamp":1790830835723,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the clinical efficacy, safety and prognostic influencing factors of carbon ion radiotherapy (CIRT) in patients with limited-stage small-cell lung cancer (LS-SCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The clinical data of 39 patients with LS-SCLC who received CIRT from June 2020 to August 2026 were retrospectively analyzed. Survival outcomes and adverse reactions were evaluated, and Cox regression was used to analyze prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All patients completed the treatment. The 3-month objective response rate (ORR) was 64.10%. The 1- and 2-year local control rates were both 91.2%. The 1- and 2-year overall survival (OS) rates were 91.65% and 62.45%, with a median OS of 44 months. The 1- and 2-year progression-free survival (PFS) rates were 72.00% and 47.77%, with a median PFS of 24 months. Serum levels of NSE, CYFRA21-1, SCC and CEA decreased significantly after treatment. Acute treatment-related adverse reactions were mainly grade I-II and could be relieved after symptomatic treatment. Stratified Cox regression indicated that KPS score was an independent protective factor for OS. Univariate analysis suggested that the magnitude of post-treatment reduction in SCC and CYFRA21-1 was potentially associated with survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CIRT achieves favorable local tumor control with low acute radiotherapy-related toxicity, and can serve as an alternative therapeutic option for LS-SCLC. This is a single-center, small-sample retrospective study, and the conclusions regarding efficacy and prognosis need to be further verified in larger-sample cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1898779","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:50:13Z","timestamp":1790830213000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival and prognostic factors analysis of carbon ion radiotherapy for limited-stage small cell lung cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Xuexue","family":"Liang","sequence":"first","affiliation":[{"name":"School of Public Health, Gansu University of Chinese Medicine","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinli","family":"Gong","sequence":"additional","affiliation":[{"name":"School of Public Health, Gansu University of Chinese Medicine","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihe","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department I, Radiation Therapy Center, Gansu Wuwei Tumour Hospital","place":["Wuwei, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Tian","sequence":"additional","affiliation":[{"name":"Follow-up Office, Gansu Wuwei Tumour Hospital","place":["Wuwei, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Public Health, Gansu University of Chinese Medicine","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bole","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Public Health, Gansu University of Chinese Medicine","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglin","family":"Li","sequence":"additional","affiliation":[{"name":"Department I, Radiation Therapy Center, Gansu Wuwei Tumour Hospital","place":["Wuwei, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengqing","family":"Li","sequence":"additional","affiliation":[{"name":"Follow-up Office, Gansu Wuwei Tumour Hospital","place":["Wuwei, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yancheng","family":"Ye","sequence":"additional","affiliation":[{"name":"Department I, Radiation Therapy Center, Gansu Wuwei Tumour Hospital","place":["Wuwei, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanshan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Follow-up Office, Gansu Wuwei Tumour Hospital","place":["Wuwei, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03216-3","article-title":"SEOM-GECP clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)","volume":"25","author":"Garc\u00eda-Campelo","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102606","article-title":"Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy","volume":"120","author":"Chen","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1674-4136.2025.02.012","article-title":"A comparative study of the clinical efficacy and safety of chemotherapy combined with hypofractionated radiotherapy versus conventional fractionated radiotherapy for limited-stage small cell lung cancer","volume":"17","author":"Wei","year":"2025","journal-title":"Chin J Tumor Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/pro6.1205","article-title":"Progress in radiotherapy for small\u2010cell lung cancer","volume":"7","author":"Yang","year":"2023","journal-title":"Precis Radiat Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/s2213-2600(24)00189-9","article-title":"High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial","volume":"12","author":"Yu","year":"2024","journal-title":"Lancet Respir Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4774","article-title":"Comparative effectiveness and toxicity of radiotherapy regimens in limited stage small cell lung cancer: A network meta-analysis","volume":"11","author":"Zhou","year":"2022","journal-title":"Cancer Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ctro.2022.06.005","article-title":"Value of carbon-ion radiotherapy for early stage non-small cell lung cancer","volume":"36","author":"Xiong","year":"2022","journal-title":"Clin Trans Radiat Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14950","article-title":"Carbon\u2010ion radiotherapy for urological cancers","volume":"29","author":"Ishikawa","year":"2022","journal-title":"Int J Urol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12911-024-02553-9","article-title":"Optimizing double-layered convolutional neural networks for efficient lung cancer classification through hyperparameter optimization and advanced image pre-processing techniques","volume":"24","author":"Musthafa","year":"2024","journal-title":"BMC Med Inform Decis Mak"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109553","article-title":"Metrics of dose to highly ventilated lung are predictive of radiation-induced pneumonitis in lung cancer patients","volume":"182","author":"Flakus","year":"2023","journal-title":"Radiother Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.16073\/j.cnki.cjcpt.2024.14.06","article-title":"Evaluation of the efficacy of carbon ion radiotherapy for patients with limited-stage small cell lung cancer","volume":"31","author":"Zhang","year":"2024","journal-title":"Chin J Cancer Prevent Treatment"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/acm2.14321","article-title":"The sensitivity of radiobiological models in carbon ion radiotherapy (CIRT) and its consequences on the clinical treatment plan: Differences between LEM and MKM models","volume":"25","author":"G\u00f3ra","year":"2024","journal-title":"J Appl Clin Med Phys"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmp.2025.105042","article-title":"Comparison of LEM and MKM based RBE-weighted doses from microdosimetric measurements with silicon 3D microdosimeter","volume":"136","author":"Data","year":"2025","journal-title":"Phys Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: A review","volume":"333","author":"Kim","year":"2025","journal-title":"Jama"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2024.101465","article-title":"Review of recent improvements in carbon ion radiation therapy in the treatment of glioblastoma","volume":"9","author":"Koosha","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3769\/radioisotopes.64.443","article-title":"15 clinical results of carbon ion radiotherapy for locally advanced uterine cervical cancer","volume":"64","author":"Wakatsuki","year":"2015","journal-title":"Radioisotopes"},{"key":"B17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/pro6.1120","article-title":"Ion therapy guideline (Version 2020)","volume":"5","author":"Zhang","year":"2021","journal-title":"Precis Radiat Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9060066","article-title":"Carbon ion radiotherapy: A review of clinical experiences and preclinical research, with an emphasis on DNA damage\/repair","volume":"9","author":"Mohamad","year":"2017","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70070","article-title":"Real-world analysis of treatment patterns in limited-stage small cell lung cancer: Implications for clinical practice","volume":"16","author":"Yu","year":"2025","journal-title":"Thorac Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3233\/TUB-230016","article-title":"Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission","volume":"46","author":"Muley","year":"2024","journal-title":"Tumor Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.21037\/jtd-2025-aw-1993","article-title":"Real-world evidence on the efficacy, safety, and biomarkers of immunotherapy combined with radiotherapy in limited-stage small cell lung cancer","volume":"18","author":"Liu","year":"2026","journal-title":"J Thorac Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3857\/roj.2023.00773","article-title":"Pulmonary function and toxicities of proton versus photon for limited-stage small cell lung cancer","volume":"41","author":"Seo","year":"2023","journal-title":"Radiat Oncol J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2015.01.005","article-title":"Incidence and predictors of severe acute esophagitis and subsequent esophageal stricture in patients treated with accelerated hyperfractionated chemoradiation for limited-stage small cell lung cancer","volume":"5","author":"Grant","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1186\/s12885-025-14480-7","article-title":"Immunotherapy concurrently administered with chemoradiotherapy in limited-stage small-cell lung cancer","volume":"25","author":"Long","year":"2025","journal-title":"BMC Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70125","article-title":"A comprehensive study on clinical outcomes and safety of neoadjuvant immunotherapy combined with chemotherapy in limited-stage small cell lung cancer","volume":"16","author":"Ge","year":"2025","journal-title":"Thorac Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/cas.70188","article-title":"Durvalumab post concurrent chemoradiotherapy in Japanese patients with limited-stage small-cell lung cancer in the phase 3 ADRIATIC trial","volume":"116","author":"Zenke","year":"2025","journal-title":"Cancer Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30870","article-title":"Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer","volume":"123","author":"Rwigema","year":"2017","journal-title":"Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2022.0326","article-title":"Simultaneous integrated dose reduction intensity-modulated radiotherapy effectively reduces cardiac toxicity in limited-stage small cell lung cancer","volume":"20","author":"Luo","year":"2023","journal-title":"Cancer Biol Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.06.747","article-title":"Long-term results of a phase II study of accelerated hyperfractionated thoracic radiotherapy with dose escalation to 54 Gy for limited-stage small-cell lung cancer","volume":"117","author":"Ono","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.07.1594","article-title":"Phase II study of sintilimab combined with concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer (SINCE-01 trial)","volume":"114","author":"Wang","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.07.1862","article-title":"Hypofraction radiotherapy (4Gy\/f) for limited-stage small cell lung cancer: A phase I\/II trial","volume":"120","author":"Li","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.07.100","article-title":"Durvalumab combined with concurrent chemoradiotherapy in patients with limited-stage small-cell lung cancer: A prospective, single-arm, phase II clinical trial","volume":"120","author":"Shen","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1898779\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:50:19Z","timestamp":1790830219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1898779\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":33,"alternative-id":["10.3389\/fonc.2026.1898779"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1898779","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1898779"}}